Percutaneous Coronary Intervention After Return of Spontaneous Circulation Reduces the In-Hospital Mortality in Patients with Acute Myocardial Infarction Complicated by Cardiac Arrest

Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock

“…Importance of More Potent Antiplatelet Therapy in Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock C urrent treatment of acute myocardial infarction complicated by cardiogenic shock (CS) or resuscitated cardiac arrest (CA) (whether in hospital or out of hospital) almost always includes percutaneous coronary intervention (PCI) as studies have shown improved in-hospital and long-term outcomes with PCI compared with medical therapy alone. [1][2][3] Use of dual antiplatelet therapy with aspirin and a P2Y 12 receptor inhibitor is considered standard of care with PCI regardless of the circumstance, unless the patient is at a very high risk of bleeding, although the post-PCI duration of therapy is often debated. 3 There are 4 oral P2Y 12 receptor inhibitors currently in use in the United States, with clopidogrel dominating the market at approximately 60%, ticagrelor accounting for approximately 24% of the market, and prasugrel having approximately 17% of the market, with ticlopidine rarely used at less than 5% of the market.…”